Tuesday, January 31, 2012

Muscle TypesImage by labguest via FlickrIn some patients, multiple sclerosis attacks the body in such a way that leg muscles begin to deteriorate, and many patients end up with a cane or walker before they reach old age.
But mobility problems often do not appear until the disease has progressed. Doctors have a hard time identifying mobility deficits, or muscle weakness until the symptoms became more obvious.
But according to a new study, a series of tests for muscle endurance and gait could identify....read more

Bookmark and Share
Enhanced by Zemanta

Saturday, January 28, 2012

MS Society of Canada - Living with MS - MS Updates

MS Update
January 27, 2012
 
Reports from seven multi-disciplinary teams investigating CCSVI (chronic cerebrospinal venous insufficiency) in MS indicate that they are making good progress toward providing essential data and critical analysis as these two-year projects move toward their completion. The studies were launched on July 1, 2010 with a more than $ 2.4 million commitment from the MS Society of Canada and the National MS Society (USA). The ongoing work by the seven teams will help inform the design of an early-phase clinical trial that is expected to launch in late spring 2012 with funding from the MS Society of Canada and the Canadian Institutes of Health Research (CIHR).
The research teams have recruited and scanned a broad spectrum of people with MS and others to build understanding of who may be affected by CCSVI. In addition they are refining CCSVI imaging methods for accuracy and consistency to reliably validate the occurrence of CCSVI and understand its implications in


Bookmark and Share
Enhanced by Zemanta
English: Progression types of Multiple sclerosisImage via Wikipedia
An interesting article

Have we been looking at Multiple Sclerosis all wrong?
Enhanced by Zemanta

Friday, January 13, 2012

Friday, January 13, 2012
Sask. MS patients to U.S. for 'liberation' trial
REGINA -- Saskatchewan says it will send multiple sclerosis patients to the U.S. for the clinical trial of a controversial treatment -- an announcement that prompted more than 100 applications within hours.
Premier Brad Wall said a New York state doctor is in the final stages of getting U.S. federal approval for what's believed to be the largest "liberation" therapy trial of its type. The province is providing $2.2 million so 86 MS patients can be included in the two-year, double-blind trial at the Albany Medical Center, said Wall.
The procedure is not currently offered in Canada and some patients have traveled around the world to seek it out despite it having not been proven to work.
"While we're talking here, people are raising money and having bake sales and getting the support of neighbours and friends to try to go somewhere to have the treatment. Well, we should find some answers," said Wall.
The double-blind aspect of the study means only half of the patients will actually receive the treatment. The patient and the physicians who do the followup will not know if they got the treatment.
"They'll knowingly volunteer for the trials understanding that they may not get the treatment, which of course is probably what many would like to have. But they're going to do it in the interest of science, in the interest of demonstrating the efficacy of this treatment or coming to some other conclusion, which would also be helpful," said Wall.
More than 130 applications were submitted within five hours of Wall's announcement. People have until Feb. 24 to apply either through the government's website or a toll-free line.
The province says those selected will be contacted and the first patients can expect to travel to Albany in March.
"We know that there will be some applicants that will be disappointed, but I can assure you that all will be given an equal chance," said Health Minister Don McMorris.
The treatment is based on a hypothesis by Italian vascular surgeon Dr. Paolo Zamboni that a condition he dubbed chronic cerebrospinal venous insufficiency, or CCSVI, may be linked to multiple sclerosis. The theory suggests narrowed neck veins create a backup of blood that can lead to lesions in the brain and inflammation.
Liberation therapy involves opening up blocked neck veins. But the idea that the condition might be linked to the progressive neurological disease has divided the medical community.
With a population of slightly more than one million, Saskatchewan has some of the highest rates of MS in the country. An estimated 3,500 Saskatchewan residents have MS. Canada's rate of MS is among the highest in the world at 240 per 100,000 people. On the Prairies, the rate is 340 per 100,000 people.
Saskatchewan was the first province to pledge clinical trials when it put up $5 million and issued a call for proposals in October 2010. The goal was to proceed with clinical trials by spring 2011.
-- The Canadian Press
Trials seem delayed
Manitoba was slated to announce last month which researchers in this province will share $5 million earmarked for clinical trials of the "liberation" therapy.
But the government has apparently delayed the announcement. Also, it won't say how many research proposals it received, how many were chosen for peer review or how many made the short list.
Last spring, with significant fanfare, Manitoba earmarked $5 million and put out a call for proposals relating to the liberation-therapy treatment.
The province's deadline to receive proposals was Sept. 30, and scientific peer review was to be completed in November.
Despite at least two separate freedom-of-information requests, a spokesman for Manitoba Health said due to the Manitoba Health Research Council's protocol, the number of proposals, the names of applicants and individuals sitting on the review committee cannot be released to the public.
Bookmark and Share
Enhanced by Zemanta

Tuesday, January 10, 2012

January 10, 2012

Research proving link between virus and MS could point the way to treatment and prevention, Queen Mary, University of London


A new study from researchers at Queen Mary, University of London shows how a particular virus tricks the immune system into triggering inflammation and nerve cell damage in the brain, which is known to cause MS.
Previous research has suggested a link between the Epstein-Barr virus (EBV) and multiple sclerosis but the research has remained controversial since scientists have so far failed to substantiate the link.

The new study proves the virus is involved in a manner more sophisticated and subtle than previously imagined, and may offer new ways to treat or prevent the disease. read article here

Bookmark and Share
Enhanced by Zemanta

Saturday, January 7, 2012

Managing your fatigue...

Some good tips on managing your fatigue.

I feel it all comes down to listening to your body! No one else knows how you feel better than "YOU"

Meds are listed on pg .41. I have had success with Amantadine 


Bookmark and Share
Enhanced by Zemanta

"60 Minutes" investigates online stem cell fraud - CBS News



(CBS News)
Dr. Joanne Kurtzberg of Duke University tells Scott Pelley that stem cells purchased from one of the hundreds of websites promising stem cell cures for incurable diseases could actually cause a patient serious harm. The chief scientific officer for Duke's stem cell research program spoke to Pelley as part of an eight-month investigation into the illicit stem cell industry.
In the report, "60 Minutes" cameras capture a disgraced doctor trying to sell an unproven stem cell treatment to the parents of a child with cerebral palsy. Pelley's investigation will be broadcast on "60 Minutes" on Sunday, Jan. 8 at 8 p.m. ET/PT.
Kurtzberg decries the websites offering unproven stem cell remedies for what are currently incurable diseases like autism, multiple sclerosis, Alzheimer's and every kind of cancer. She hears from patients who see those websites and has to inform them that thus far, stem cells have been used to successfully treat leukemia and a few rare genetic diseases and nothing else. "It's very dishonest to mislead people when there is nothing you can do," says Kurtzberg. "I believe stem cells have a lot of promise, but we are way at the infancy," she tells Pelley.
"60 Minutes" worked with Gary and Judy Susser, parents of Adam, who has cerebral palsy, to investigate one of the online purveyors of stem cell treatments, Stem Tech Labs of Ecuador. Such labs are offshore because what they are doing is mostly illegal in the U.S. The lab, run by an American doctor named Dan Ecklund whose license to practice medicine was revoked in Alabama, promises a "modern day miracle" and "treating or curing over 70 diseases." "60 Minutes" cameras captured Ecklund on a teleconference from Ecuador promising the Sussers that Adam would have a "75 percent chance...he would have a noticeable improvement." He would come to Florida to administer four stem cell transplants for which he would charge $5,000 each. In a Miami-area hotel room set with hidden cameras, Pelley confronts Ecklund about his intentions to treat the child.
"60 Minutes" purchased some stem cells from Ecklund's website and had Kurtzberg examine them in her lab at Duke. Dr. Kurtzberg discovered that only 100 of the 20 million umbilical cord blood stem cells bought for $5,000 were still alive. The dead cells are cellular debris and dangerous says Kurtzberg. "There are huge dangers if you inject that into someone's blood or spinal fluid because all these little fragments and debris would get trapped somewhere in the bloodstream and could cause a stroke...do a great deal of harm," Kurtzberg tells Pelley.
Adam, 11, did not get the treatments; his parents had been down that route before in 2003 when they took him to Mexico for similar treatments that produced no miracles. The Sussers want others to beware. "People are preyed upon by hucksters and charlatans... It's about getting rich at someone's expense," says Gary Susser. "And people with a special child don't need anymore expense...heartache...false promises. They need the truth and they need hope."


Bookmark and Share
Enhanced by Zemanta

Wednesday, January 4, 2012

Copaxone repairs nerve tissue in multiple sclerosis patients, said Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) today in reporting the results of a 12-month MRI study on the evolution of multiple sclerosis lesions. The study was published in the January issue of "Frontiers in Bioscience".

“These data indicate that treatment with Copaxone resulted in a measureable amount of tissue repair in study patients,” said the lead research Dr. Robert Zivadinov, Director of the Buffalo Neuroimaging Analysis Center at the University at Buffalo. “The observed increases in magnetization transfer ratio (MTR) point to a potential for remyelination. Overall, these findings contribute to the vast body of research that supports the long-term efficacy and safety of the therapy."

The researchers found that multiple sclerosis patients treated with Copaxone experienced significantly increased magnetization transfer ratio (MTR) - a nonconventional MRI technique used to investigate abnormalities in brain structures, and increased values indicate potential remyelination (re-generation of the nerve's myelin sheath) and axonal tissue repair in the patients' brains.

Teva added that this was the first study to evaluate multiple sclerosis lesions as potential evidence for remyelination in patients treated with Copaxone.

Published by Globes [online], Israel business news - www.globes-online.com - on January 3, 2012
Bookmark and Share
Enhanced by Zemanta